[go: up one dir, main page]

ATE401892T1 - Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand - Google Patents

Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand

Info

Publication number
ATE401892T1
ATE401892T1 AT00983101T AT00983101T ATE401892T1 AT E401892 T1 ATE401892 T1 AT E401892T1 AT 00983101 T AT00983101 T AT 00983101T AT 00983101 T AT00983101 T AT 00983101T AT E401892 T1 ATE401892 T1 AT E401892T1
Authority
AT
Austria
Prior art keywords
futting
state
pharmaceutical preparations
preparations containing
containing oxcarbazepine
Prior art date
Application number
AT00983101T
Other languages
English (en)
Inventor
Steffen Lang
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE401892T1 publication Critical patent/ATE401892T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00983101T 1999-11-02 2000-10-31 Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand ATE401892T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925962.4A GB9925962D0 (en) 1999-11-02 1999-11-02 Organic compounds

Publications (1)

Publication Number Publication Date
ATE401892T1 true ATE401892T1 (de) 2008-08-15

Family

ID=10863836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00983101T ATE401892T1 (de) 1999-11-02 2000-10-31 Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand

Country Status (25)

Country Link
US (3) US20060079502A1 (de)
EP (1) EP1242091B1 (de)
JP (3) JP2003514780A (de)
KR (1) KR100493836B1 (de)
CN (1) CN1407894A (de)
AT (1) ATE401892T1 (de)
AU (1) AU777705B2 (de)
BR (1) BR0015188A (de)
CA (1) CA2388609C (de)
CZ (1) CZ302847B6 (de)
DE (1) DE60039629D1 (de)
ES (1) ES2311001T3 (de)
GB (1) GB9925962D0 (de)
HK (1) HK1050839B (de)
HU (1) HU227685B1 (de)
IL (3) IL149147A0 (de)
MX (1) MXPA02004389A (de)
NO (1) NO330947B1 (de)
NZ (1) NZ518378A (de)
PL (1) PL200273B1 (de)
RU (1) RU2330666C2 (de)
SK (1) SK287479B6 (de)
TR (1) TR200200951T2 (de)
WO (1) WO2001032183A2 (de)
ZA (1) ZA200203394B (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
US20040185095A1 (en) * 2002-05-31 2004-09-23 Hanshermann Franke Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
US7465723B2 (en) * 2002-08-06 2008-12-16 Novartis Use of carboxamides for the treatment of tinnitus
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
RU2369393C2 (ru) * 2003-09-03 2009-10-10 Новартис Аг Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
WO2006046105A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Oxcarbazepine dosage forms
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007008576A2 (en) * 2005-07-08 2007-01-18 Taro Pharmaceuticals U.S.A., Inc. Oxcarbazepine formulation
WO2007029093A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of oxcarbazepine
AU2006337141A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
JP2008540346A (ja) * 2006-01-31 2008-11-20 テバ ファーマシューティカル インダストリーズ リミティド オキシカルバゼピンの医薬製剤及びその調製方法
EP2026815B1 (de) 2006-04-26 2011-01-26 Supernus Pharmaceuticals, Inc. Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2008115442A1 (en) 2007-03-16 2008-09-25 Concert Pharmceuticals, Inc. Inhibitors of cholesterol ester transfer protein
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
CA2686545C (en) * 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
EP2527336A1 (de) 2007-04-25 2012-11-28 Concert Pharmaceuticals Inc. Deuterium Analoga von Cilostazol
CN101687868B (zh) 2007-05-01 2012-12-12 康塞特医药品公司 吗啡烷化合物
EP3357923B1 (de) 2007-05-01 2019-11-13 Concert Pharmaceuticals Inc. Morphinanverbindungen
CA2685924A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl)acetamides
EP4183787A1 (de) 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinanverbindungen
PL2003120T3 (pl) 2007-06-12 2010-04-30 Concert Pharmaceuticals Inc Pochodne azapeptydu jako inhibitory proteazy HIV
EP2212298B1 (de) * 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuteriertes etravirin
JP5292413B2 (ja) 2008-02-29 2013-09-18 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
US20100221221A1 (en) * 2008-08-12 2010-09-02 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
EA023962B1 (ru) 2008-09-19 2016-07-29 Консерт Фармасьютикалз Инк. Дейтерированные морфинановые соединения
EP3603674B1 (de) 2008-10-30 2025-02-26 Sun Pharmaceutical Industries, Inc. Kombination von morphinanverbindungen und antidepressivum zur behandlung von hartnäckigen und chronischen schmerzen
US20120053169A1 (en) 2008-10-30 2012-03-01 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
US9096646B2 (en) 2008-11-04 2015-08-04 Anchor Therapeutics, Inc. CXCR4 receptor compounds
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
BRPI1009199A2 (pt) 2009-03-17 2016-03-08 Concert Pharmaceuticals Inc compostos de pirazinoisoquinolina
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
WO2011005520A1 (en) 2009-06-23 2011-01-13 Concert Pharmaceuticals, Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2536696A1 (de) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidinderivate
EP2566494B1 (de) 2010-02-26 2017-11-29 Acer Therapeutics, Inc. Cxcr4-rezeptorverbindungen
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2011109464A1 (en) 2010-03-02 2011-09-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
EP2616467A1 (de) 2010-09-13 2013-07-24 Concert Pharmaceuticals Inc. Substituierte azaindole
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
JP2014506603A (ja) 2011-02-25 2014-03-17 コンサート ファーマシューティカルズ インコーポレイテッド ２−アミノ−ナフチリジン誘導体
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
ME02749B (de) 2011-05-18 2018-01-20 Concert Pharmaceuticals Inc Deuterierte ivacaftor-derivate
US20140296263A1 (en) 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
CA2860740A1 (en) 2012-01-09 2013-07-18 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
KR20150002779A (ko) 2012-04-13 2015-01-07 콘서트 파마슈티컬즈, 인크. 치환된 크산틴 유도체
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
PL3450434T3 (pl) 2012-06-15 2021-10-04 Concert Pharmaceuticals, Inc. Deuterowane pochodne ruksolitynibu
US10017445B2 (en) 2012-07-12 2018-07-10 Concert Pharmaceuticals, Inc. Deuterated idebenone
EP3492472A1 (de) 2012-08-17 2019-06-05 Concert Pharmaceuticals Inc. Deuteriertes baricitinib mit verbesserter metabolischer stabilität als jak1 und jak2 kinase inhibitor zur behandlung von rheumatoider arthritis
MY178621A (en) 2012-11-19 2020-10-19 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
WO2014100431A1 (en) 2012-12-20 2014-06-26 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
WO2014100733A1 (en) 2012-12-21 2014-06-26 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP3492470A1 (de) 2013-03-15 2019-06-05 Concert Pharmaceuticals, Inc. Deuteriertes palbociclib mit verbesserter metabolischer stabilität
EP2968268B1 (de) 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitoren des udp-glucose:n-acyl-sphingosin-glucosyltransferase enzyms
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
EP3021861A1 (de) 2013-07-18 2016-05-25 Anchor Therapeutics, Inc. Apj-rezeptorverbindungen
WO2015031741A1 (en) 2013-08-30 2015-03-05 Concert Pharmaceuticals, Inc. Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor
WO2015063670A1 (en) * 2013-10-30 2015-05-07 Wockhardt Limited Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
CN106459056A (zh) 2014-02-10 2017-02-22 康塞特医药品公司 经取代的三唑苯二氮卓
EP3131554A1 (de) 2014-04-18 2017-02-22 Concert Pharmaceuticals Inc. Verfahren zur behandlung von hyperglykämie
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
US10377718B2 (en) 2014-06-06 2019-08-13 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
EP4180041A1 (de) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Verbindungen und verfahren zur behandlung von krebs
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
EP3265440A1 (de) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuteriertes emricasan
CA2981495C (en) 2015-03-31 2023-09-26 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
CA2994169A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
WO2017053455A1 (en) 2015-09-21 2017-03-30 Concert Pharmaceuticals, Inc. Administration of deuterated cftr potentiators
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
RU2021133849A (ru) 2015-12-09 2022-03-21 Рисерч Трайэнгл Инститьют Улучшенные агонисты апелинового рецептора (apj) и их использование
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
SI3452039T1 (sl) 2016-05-04 2024-12-31 Sun Pharmaceutical Industries, Inc. Zdravljenje motnje izpadanja las z devteriranimi inhibitorji jak
EP4335500A3 (de) 2016-07-04 2024-05-08 Avanir Pharmaceuticals, Inc. Verfahren zur synthese von deuteriertem dextromethorphan
EP3490538A4 (de) 2016-08-01 2020-03-18 The Brigham and Women's Hospital, Inc. Partikel zur verabreichung von proteinen und peptiden
EP3589659A4 (de) 2017-02-28 2021-03-24 Mayo Foundation for Medical Education and Research Verbindungen und verwendung zur behandlung von krebs
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
MX2019013769A (es) 2017-05-19 2020-07-20 Superb Wisdom Ltd Derivados de resiquimod.
CA3082834A1 (en) 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
JP2022553862A (ja) * 2019-11-08 2022-12-26 リンドラ セラピューティクス， インコーポレイティド 活性剤投与用胃内滞留型システム
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
KR20230093504A (ko) 2020-10-28 2023-06-27 썬 파마슈티칼 인더스트리즈 인코포레이티드 중수소화된 jak 억제제를 이용한 탈모 장애의 치료를 위한 요법
JP2024531188A (ja) 2021-08-11 2024-08-29 サン ファーマシューティカル インダストリーズ，インコーポレイテッド 重水素化ｊａｋ阻害剤による脱毛障害の治療
JP2024532765A (ja) 2021-08-12 2024-09-10 サン ファーマシューティカル インダストリーズ，インコーポレイテッド Ｊａｋ阻害剤のプロドラッグを用いたｊａｋ阻害応答性障害の治療
CN119255806A (zh) 2022-05-04 2025-01-03 太阳医药工业公司 用于用氘化jak抑制剂进行治疗的剂量方案

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20020022056A1 (en) * 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets

Also Published As

Publication number Publication date
NO330947B1 (no) 2011-08-22
HK1050839A1 (en) 2003-07-11
ES2311001T3 (es) 2009-02-01
IL149147A (en) 2010-11-30
KR20020049004A (ko) 2002-06-24
PL200273B1 (pl) 2008-12-31
HUP0203556A3 (en) 2004-03-01
EP1242091B1 (de) 2008-07-23
JP2003514780A (ja) 2003-04-22
EP1242091A2 (de) 2002-09-25
AU777705B2 (en) 2004-10-28
BR0015188A (pt) 2002-11-05
CN1407894A (zh) 2003-04-02
AU1997801A (en) 2001-05-14
US20070037792A1 (en) 2007-02-15
CA2388609A1 (en) 2001-05-10
SK287479B6 (sk) 2010-11-08
NZ518378A (en) 2004-10-29
SK5842002A3 (en) 2002-08-06
DE60039629D1 (de) 2008-09-04
JP2007224041A (ja) 2007-09-06
RU2002113752A (ru) 2004-01-10
NO20022058D0 (no) 2002-04-30
TR200200951T2 (tr) 2003-01-21
HK1050839B (zh) 2009-01-30
CZ20021529A3 (cs) 2002-08-14
WO2001032183A2 (en) 2001-05-10
MXPA02004389A (es) 2002-09-02
NO20022058L (no) 2002-06-27
US20090252793A1 (en) 2009-10-08
RU2330666C2 (ru) 2008-08-10
HUP0203556A2 (hu) 2003-02-28
GB9925962D0 (en) 1999-12-29
CZ302847B6 (cs) 2011-12-14
PL366314A1 (en) 2005-01-24
IL205504A0 (en) 2011-07-31
JP2012211202A (ja) 2012-11-01
IL149147A0 (en) 2003-01-12
KR100493836B1 (ko) 2005-06-08
ZA200203394B (en) 2003-07-29
US20060079502A1 (en) 2006-04-13
WO2001032183A3 (en) 2002-07-04
CA2388609C (en) 2011-01-04
HU227685B1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
ATE401892T1 (de) Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand
HUP0101293A2 (hu) AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
IL135335A0 (en) Method for inhibiting or preventing hormone induced adverse effects and novel pharmaceutical compositions comprising carotenoids
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
ATE176482T1 (de) Asp-b28-insulinkristalle
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
ATE263571T1 (de) Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE243196T1 (de) Piperidine und pyrrolidine
ATE292453T1 (de) Antivirale arznei
HK1068606A1 (en) Novel aminobenzoephenones
DE50000864D1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
NZ514911A (en) Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
AU2001289762A1 (en) Pharmaceutical extemporary compositions
DE50005282D1 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
ES2128966A1 (es) Composiciones farmaceuticas parenterales a base de calcitoninas sinteticas, de ph controlado, con bajo indice de dolor y buena estabilidad.
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen
DE69938347D1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi
UA26082C2 (uk) Препарат для регулюваhhя ткаhинного обміhу

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242091

Country of ref document: EP